|
1 kits (10 Vials)
| Yawan: | |
|---|---|
▎ Tsarin Maz
Source: PubChem |
Jeri: AEGTFTSDVSSYLEGQAAKFIAWLVKGRG Tsarin kwayoyin halitta: C 207H 317N 45O65 Nauyin Kwayoyin: 4476g/mol Lambar CAS: 2259884-03-0 PubChem CID: 167312357 Ma'ana: GLXC-26803 |
▎ Maz Binciken
Menene asalin binciken Maz?
Fitaccen batu na kiba a duniya da cututtuka masu alaƙa:
Kiba da kiba sun ƙara tsananta ƙalubalen lafiyar jama'a a duniya. A cewar World Obesity Atlas, adadin masu kiba a duniya ya kai miliyan 764 a shekarar 2020 kuma ana sa ran zai haura biliyan 1 nan da shekarar 2030. Kiba na iya haifar da matsaloli masu yawa na kiwon lafiya, kamar cututtukan zuciya da jijiyoyin jini da kuma nau'in metabolism na 2, wanda ke matukar shafar ingancin rayuwar mutum da albarkatun kiwon lafiya na duniya. Wannan ya sa masu bincike su binciko ingantattun hanyoyin magani, musamman sabbin magunguna.
Tushen haɓakar magunguna na tushen incretin:
Tun lokacin da aka gabatar da manufar incretin a cikin 1932, bincike mai alaƙa yana ci gaba a hankali. A cikin 1987, an gano GLP-1 a matsayin babban mai sarrafa insulin a cikin pancreas, kuma an haɓaka tsarin jiyya don nau'in 2 na metabolism dangane da incretin. A cikin 2005, exenatide, farkon GLP-1 mai karɓar agonist na duniya (GLP-1RA), an amince da shi don tallatawa, yana shimfida tushe mai ƙarfi da tushe mai amfani don bincike da haɓaka sabbin magunguna na tushen incretin kamar Maz. Maz analog ne na mammalian oxyntomodulin (OXM). A matsayin sabon-ƙarni mai dual agonist wanda ke niyya GLP-1R da GCGR, yana da na'ura ta musamman na ayyuka biyu da kuma faffadan bege a cikin maganin asarar nauyi da cututtukan da ke da alaƙa.
Menene tsarin aikin Maz?
Tasirin Agonistic akan mai karɓar glucagon-kamar peptide-1 (GLP-1):
GLP-1 wani hormone ne na hanji wanda zai iya inganta siginar insulin kuma ya hana fitar da glucagon ta hanyar dogara ga glucose, ta haka ne rage matakan glucose na jini [1] . A matsayin GLP-1 agonist mai karɓa, Maz yana kwaikwayon aikin GLP-1, yana haɓaka haɓakar insulin da rage sakin glucagon, wanda ke taimakawa wajen daidaita glucose na jini. Haka kuma, GLP-1 agonists mai karɓa na iya jinkirta zubar da ciki, haɓaka satiety, da rage cin abinci, wanda ke da fa'ida don sarrafa nauyi [1, 2].
Tasirin Agonistic akan mai karɓar glucagon:
Glucagon na iya haɓaka rushewar glycogen hanta da gluconeogenesis, wanda ke haifar da haɓakar glucose na jini. Maz, ta hanyar kunna mai karɓar glucagon, na iya daidaita al'amuran da yawa na metabolism na glucose, samun kyakkyawan tsari na glucose na jini. Glucagon kuma yana haɓaka lipolysis, yana taimakawa rage tarin kitse da ƙananan nauyin jiki [1, 2].
Tasirin tsari akan hawan jini:
Maz na iya rage duka systolic da diastolic hawan jini. A gefe guda, yana rage karfin jini ta hanyar daidaita glucose da lipid metabolism da inganta aikin endothelial na jijiyoyin jini; a gefe guda, yana iya rinjayar hanyoyin daidaita karfin jini kamar tsarin renin-angiotensin.
Menene takamaiman tsarin Maz don asarar nauyi?
Tsarin glucose na jini da metabolism:
A matsayin mai dual agonist na glucagon-kamar peptide-1 (GLP-1) da masu karɓar glucagon, ɗayan tasirin ilimin lissafin jiki da yawa na GLP-1 shine daidaita matakan glucose na jini. Yana inganta ƙwayar insulin, yana hana ƙwayar glucagon, yana rage glucose na jini [1] , yana jinkirta zubar da ciki, yana ƙaruwa, kuma yana rage cin abinci. Glucagon, a gefe guda, yana haɓaka lipolysis da amfani da makamashi. Sabili da haka, Maz yana kunna duka masu karɓa kuma yana daidaita matakan glucose na jini don cimma asarar nauyi. Nazarin ya nuna cewa Maz na iya rage nauyin jiki, hawan jini (systolic da diastolic), jimillar cholesterol, triglycerides, low-density lipoprotein, da matakan lipoprotein masu yawa [3] , wanda ke nuna cewa yana iya haifar da asarar nauyi da kuma inganta cututtukan da ke da alaka da kiba.
Tasiri kan ci da kuzari:
Maz na iya samun asarar nauyi ta hanyar tasiri ga ci da kuzari. A wasu gwaje-gwaje na asibiti, mahalarta sun fuskanci halayen gastrointestinal kamar rage cin abinci bayan amfani da Maz [3] . Ana iya haifar da wannan ta hanyar aikin kai tsaye na Maz akan sashin gastrointestinal ko ta hanyar tsari ta tsarin kulawa na tsakiya. Ba tare da la'akari da tsarin ba, rage cin abinci da illa masu illa na gastrointestinal zai rage yawan kuzari da inganta asarar nauyi. Bugu da ƙari, Maz na iya rinjayar ci ta hanyar daidaita masu amfani da neurotransmitters da hormones a cikin kwakwalwa. Misali, GLP-1 na iya yin aiki akan hypothalamus don daidaita ma'aunin ci da kuzari [4].
Menene takamaiman hanyoyin aiki na Maz wajen daidaita glucose na jini?
Ƙarfafa ƙwayar insulin:
Glucagon-kamar peptide-1 (GLP-1) agonists masu karɓa na iya tayar da ƙwayar insulin. A matsayin mai dual agonist na GLP-1 da masu karɓar glucagon, Maz na iya kunna mai karɓar GLP-1 don ƙaddamar da ƙwayoyin sel na sel na pancreatic don ɓoye insulin. Insulin shine babban hormone don rage glucose na jini, wanda zai iya haɓaka sel don ɗaukar glucose da rage matakan glucose na jini [1]..
Hana fitar da glucagon:
A lokaci guda, Maz na iya yin aiki akan mai karɓar glucagon don hana fitar glucagon. Glucagon da insulin suna gaba da juna a cikin tsarin glucose na jini, kuma rage fitar da shi yana taimakawa wajen rage glucose na jini [1]..
Tsarin metabolism na glucose:
Maz na iya daidaita metabolism na glucose a matakai da yawa don aiwatar da tasirin sa na hypoglycemic, kamar yana shafar metabolism na glucose a cikin hanta, tsoka, da kyallen takarda. A cikin hanta, yana rage rushewar hanta glycogen da gluconeogenesis, yana rage samar da glucose na jini; a cikin ƙwayar tsoka, yana inganta haɓakawa da amfani da glucose; a cikin adipose tissue, yana daidaita metabolism na lipid, yana rage sakin fatty acids kyauta, kuma a kaikaice yana shafar glucose na jini [1, 3]..
Tasiri kan ci da kuzari:
Nazarin ya gano cewa Maz na iya rage ci da kuzari, mai yiwuwa ta hanyar yin aiki akan masu karɓa a cikin tsarin juyayi na tsakiya da kuma daidaita hanyar siginar ci. Rage cin abinci na iya rage tushen glucose na jini kuma yana taimakawa sarrafa matakan glucose na jini [3, 5].
Canji daga asali a cikin nauyin jiki da kewayen kugu.
a.Kashi na canji daga asali a cikin nauyin jiki akan lokaci. b. Canja daga asali a cikin nauyin jiki akan lokaci.
Source:PubMed [2]
Menene aikace-aikacen Maz?
Jiyya na nau'in 2 metabolism:
Wani bazuwar, makafi sau biyu, gwajin gwaji na mataki na 2 na wuribo ya nuna cewa Maz, mai sarrafa agonist na mako-mako na glucagon-kamar peptide 1 (GLP-1) da masu karɓar glucagon, sun nuna inganci da aminci a cikin marasa lafiya na kasar Sin tare da nau'in 2 metabolism [1].
Aikace-aikace a cikin asarar nauyi:
Bincike akan marasa lafiya tare da kuma ba tare da metabolism ba: Bita na yau da kullun da meta-bincike ya nuna cewa Maz na iya rage nauyin jikin manya da kyau tare da ko ba tare da metabolism ba [3] . Binciken ya haɗa da gwaje-gwajen sarrafawa guda bakwai tare da jimlar mahalarta 680. Sakamakon ya nuna cewa idan aka kwatanta da placebo, Maz ya haifar da raguwa mai mahimmanci a cikin nauyin jiki (ma'anar bambanci [MD] = -6.22%, 95% tazarar amincewa [CI]: -8.02% zuwa -4.41%, I⊃2; = 90.0%) (Nalisa DL, 2024). Ƙungiya da ƙididdiga na meta-regression sun gano cewa marasa lafiya ba tare da metabolism ba suna da asarar nauyi mai mahimmanci, kuma marasa lafiya da aka bi da su don makonni 24 sun sami raguwa mafi girma fiye da waɗanda aka bi da su don makonni 12-20 [3].
Aikace-aikace a cikin manya na kasar Sin masu kiba ko kiba:
Binciken tsakiyar lokaci na bazuwar, kashi biyu (ƙananan kashi har zuwa 6mg da babban kashi 9mg), makafi biyu, gwajin gwaji na Phase 2 da aka gudanar a cikin manya na kasar Sin tare da kiba ko kiba ya nuna cewa Maz yana da lafiya kuma yana da tasiri a cikin wannan yawan a lokacin lokacin jiyya na makonni 24, yana kawo gagarumin hasara mai ma'ana ta asibiti [2] . A cikin binciken, manya masu kiba (BMI ≥ 24 kg / m²) tare da hyperphagia da / ko aƙalla ɗaya daga cikin cututtukan da ke da alaƙa da kiba, ko manya da kiba (BMI ≥ 28 kg / m²) an ba da izini don karɓar Maz na mako-mako a cikin allurai na 3mg, 6mg ko 4mg. Sakamakon ya nuna cewa daga asali zuwa mako na 24th, ma'anar canji a cikin nauyin jiki shine -6.7% (kuskuren daidaitattun 0.7) a cikin 3mg Maz kungiyar, -10.4% (0.7) a cikin 4.5mg kungiyar, -11.3% (0.7) a cikin 6mg kungiyar, da kuma 1.0% (0.7). Idan aka kwatanta da placebo, bambancin jiyya ya kasance daga -7.7% zuwa -12.3% (duk p <0.0001) [2].
A ƙarshe, a matsayin sabon agonist dual- target agonist, ta hanyoyi da yawa kamar daidaita glucose na jini, haɓaka metabolism mai, da hana ci abinci, Maz na iya haɓaka matakan glucose na jini yadda yakamata na marasa lafiya tare da nau'in metabolism na nau'in 2 kuma yana taimakawa mutane masu kiba su rasa nauyi. Yana shigar da sabon kuzari a cikin maganin cututtukan da ke haifar da rayuwa kuma ana tsammanin zai rage nauyin kiba da cututtukan da ke da alaƙa a duniya.
Game da Marubuci
Abubuwan da aka ambata a sama duk bincike ne, gyara su kuma Cocer Peptides ne suka haɗa su.
Mawallafin Jaridar Kimiyya
Zhang B ƙwararren malami ne wanda ke da alaƙa da shahararrun ƙungiyoyi. Wadannan sun hada da Kwalejin Kiwon Lafiya ta Peking Union, Kwalejin Kimiyyar Kiwon Lafiya ta kasar Sin - Kwalejin Kiwon Lafiya ta Peking Union, Sin - Asibitin Abota na Japan, Guizhou Equipment Mfg Polytech, Jami'ar Shanghai Jiao Tong, Jami'ar Utara Malaysia, Cibiyar Fasaha ta Yingkou, Jami'ar Zhejiang, da Asibitin Kwalejin Kiwon Lafiya ta Peking Union. Irin waɗannan bambance-bambancen haɗin kai na cibiyoyi suna nuna faffadan iliminsa da na bincike.
Dangane da bincike, Zhang B yana da nau'ikan batutuwa masu yawa. Kwarewarsa ya haɗa da Endocrinology & Metabolism, General & Internal Medicine, Oncology, Cardiovascular System & Cardiology, da Radiology, Medicine Nuclear & Medical Imaging. Ayyukansa a waɗannan fagagen suna nuna zurfin iliminsa da gagarumar gudunmawar haɓaka ilimin likitanci da inganta ayyukan kiwon lafiya. An jera Zhang B a cikin ambaton ambaton [1].
